Palliative Uses of Methylphenidate in Patients With Cancer: A Review
The DOI matches its OpenAlex record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
PURPOSE: Cancer is, unfortunately, often a terminal disease. The goal of therapy for many patients with cancer is palliation of symptoms common at the end of life, including pain, depression, and cognitive dysfunction. Methylphenidate is a psychostimulant most commonly used in the treatment of attention deficit hyperactivity disorder. In this report, we review the use of methylphenidate in the palliative care of patients with cancer. METHODS: This review was written on the basis of a computerized literature search of Medline. We considered all English language publications from 1966 to present using the following key words: methylphenidate, palliative care, and cancer. Forty-nine articles were identified as being relevant for this review. RESULTS: On the basis of this review, we came to the conclusion that methylphenidate is used to ameliorate opioid-induced somnolence, to augment the analgesic effects of opioids, to treat depression, and to improve cognitive function in patients with cancer. CONCLUSION: The medical literature supports the palliative use of methylphenidate in the care of patients with cancer. Further placebo-controlled trials are needed to elucidate the precise role that methylphenidate will have in providing symptom relief to dying patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Serotonin in the Paradoxical Calming Effect of Psychostimulants on Hyperactivity
Gainetdinov, R. R., Wetsel, W. C., Jones, S. R., Levin, E. D., Jaber, M., & Caron, M. G. (1999) · Science · doi:10.1126/science.283.5400.397 · Cited by 885
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575
Gill, M., Daly, G., Heron, S., Hawi, Z., & Fitzgerald, M. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000290 · Cited by 482
Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216
Wall, S. C., Gu, H., & Rudnick, G. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08574-8 · Cited by 183
Ding, Y.-S., Fowler, J. S., Volkow, N. D., Dewey, S. L., Wang, G.-J., Logan, J., Gatley, S. J., & Pappas, N. (1997) · Psychopharmacology · doi:10.1007/s002130050267 · Cited by 157
Cited by
Assessment and management of cancer-related fatigue in adults
Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14186-4 · Cited by 546
Behavioral Symptoms in Patients With Breast Cancer and Survivors
Bower, J. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3248 · Cited by 483
Henson, L. A., Maddocks, M., Evans, C., Davidson, M., Hicks, S., & Higginson, I. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00470 · Cited by 367
A Systematic Review and Meta-Analysis of the Pharmacological Treatment of Cancer-Related Fatigue
Minton, O., Richardson, A., Sharpe, M., Hotopf, M., & Stone, P. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn250 · Cited by 283
Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Stock, J. V. D., Smeets, A., Christiaens, M., Leemans, A., Hecke, W. V., et al. (2011) · Human Brain Mapping · doi:10.1002/hbm.21033 · Cited by 275
Volkow, N. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00104-9 · Cited by 217
Gender differences in depression and response to psychotropic medication
Gorman, J. M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80199-3 · Cited by 195
The prevalence and pharmacotherapy of depression in cancer patients
Ng, C. G., Boks, M. P. M., Zainal, N. Z., & de Wit, N. J. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.07.034 · Cited by 138
Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care
Irwin, S. A., & Iglewicz, A. (2010) · Journal of Palliative Medicine · doi:10.1089/jpm.2010.9808 · Cited by 123
Cancer, cognitive impairment, and meditation
Biegler, K. A., Alejandro Chaoul, M., & Cohen, L. (2009) · Acta Oncologica · doi:10.1080/02841860802415535 · Cited by 111
Hurwitz, C. A., Duncan, J., & Wolfe, J. (2004) · JAMA · doi:10.1001/jama.292.17.2141 · Cited by 109
The treatment of depression in patients with advanced cancer undergoing palliative care
Price, A., & Hotopf, M. (2009) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0b013e328325d17a · Cited by 60
Ng, C. G., Boks, M. P. M., Roes, K. C. B., Zainal, N. Z., Sulaiman, A. H., Tan, S. B., & de Wit, N. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.01.016 · Cited by 52
“…of action, was suggested as for augmentation of antidepressant treatment in cancer patients (Masand and Tesar, 1995; Challman and Lipsky, 2000; Rozans et al., 2002; Kaminski and Sjogren, 2007) and is currently used in some hospitals for the treatment of depression in terminally ill patients…”
BackgroundMethodUse of adjunctive stimulants in adult bipolar depression
Dell'Osso, B., & Ketter, T. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000326 · Cited by 31
“In addition, the widespread reported use of stimulants in depressive disorders associated with medical conditions (Lazarus et al. 1992; Masand et al. 1991; Rosenberg et al. 1991; Rothenhäusler et al. 2000; Roy & Bernier, 1999 ; Rozans et al. 2002; Thomas & Lipsky, 2000 ; White et al. 1992; Woods et al. 1986) as well a…”
BackgroundRamasubbu, R., Singh, H., Zhu, H., & Dunn, J. F. (2012) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2258 · Cited by 20
Metadata
- Authors
- Rozans, M., Dreisbach, A. W., Lertora, J. J. L., & Kahn, M. J.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 335-339
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2047648732
- Cited by
- 145
- References
- 6
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.